In that study, we demonstrated that KL co-mutant cells, compared to KRAS mutant cells, show higher HBP activity, KL co-mutant tumor growth, but not KRAS mutant tumor growth, is impaired by the GFPT inhibitor azaserine in both subcutaneous xenograft and autochthonous lung tumor mouse models. Here, KRAS is linked to neoplasm.